Showing results (1-10 of 72) with videos related to
Sort By:
Pageof 8
Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society|March 25, 2009
Systems biology: a therapeutic target for tumor therapyAlbrecht Reichle, Thomas VogtCancer Microenvironment : Official Journal of the International Cancer Microenvironment Society|July 14, 2009
Principles of modular tumor therapyAlbrecht Reichle, Gerhard C HildebrandtCurrent Cancer Drug Targets|September 24, 2005
New indications for established drugs: combined tumor-stroma-targeted cancer therapy with PPARgamma agonists, COX-2 inhibitors, mTOR antagonists and metronomic chemotherapyChristian Hafner, Albrecht Reichle, Thomas VogtFrontiers in Pharmacology|April 12, 2019
A Computational Model of Tumor Growth and AnakoinosisPan Pantziarka, Lina Ghibelli, Albrecht ReichleBritish Journal of Haematology|March 12, 2002
Adoptive therapy with monocyte-derived macrophages in the setting of high-dose chemotherapy and peripheral blood stem cell transplantationStefan W Krause, Marcus Gnad, Albrecht Reichle, et al.BMC Cancer|October 21, 2018
Low-dose trofosfamide plus rituximab is an effective and safe treatment for diffuse large B-cell lymphoma of the elderly: a single center experienceRoland Christian Schelker, Wolfgang Herr, Albrecht Reichle, et al.Onkologie|July 29, 2006
Pericarditis after high-dose chemotherapy: more frequent than expected?Jurgen Bock, Anna Doenitz, Reinhard Andreesen, et al.Frontiers in Pharmacology|November 29, 2018
Lowering Etoposide Doses Shifts Cell Demise From Caspase-Dependent to Differentiation and Caspase-3-Independent Apoptosis via DNA Damage Response, Inducing AML Culture ExtinctionEmanuele Bruni, Albrecht Reichle, Manuel Scimeca, et al.Anti-Cancer Agents in Medicinal Chemistry|July 15, 2009
Targeting the tumor stroma with peroxisome proliferator activated receptor (PPAR) agonistsAnnika Bundscherer, Albrecht Reichle, Christian Hafner, et al.International Journal of Molecular Sciences|January 28, 2026
Genome Agnostic Reprogramming of Acute Myelocytic Leukemia Hallmarks by Targeting Non-Oncogene Addictions with Azacitidine Plus Pioglitazone and All-Trans Retinoic AcidDennis Christoph Harrer, Florian Lüke, Tobias Pukrop, et al.Pageof 8